Bárbara Du Rocher

Bárbara Du Rocher

Auto-generated profile, based on publicly available information

Bárbara Du Rocher

Laboratory on Thymus Research, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2012 in Cell Proliferation
Verified
Journal Article
Closed access
RBR. Binato
R. Binato
TFT. de Souza Fernandez
T. de Souza Fernandez
CLC. Lazzarotto‐Silva
C. Lazzarotto‐Silva
BRB. Du Rocher
B. Du Rocher
AMA. Mencalha
A. Mencalha
EAE. Abdelhay
E. Abdelhay

23 July 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SCStephany Corrêa
Stephany Corrêa
RBRenata Binato
Renata Binato
BRBárbara Du Rocher
Bárbara Du Rocher
MCMorgana Teixeira Lima Castelo-Branco
Morgana Teixeira Lima Castelo-Branco
LPLuciana Pizzatti
Luciana Pizzatti
EAEliana Abdelhay
Eliana Abdelhay
Background: The advanced phases of chronic myeloid leukemia (CML) are known to be more resistant to therapy. This resistance has been associated with the overexpression ofABCB1, which gives rise to the multidrug resistance (MDR) phenomenon. MDR is characterized by resistance to nonrelated drugs, and P-glycoprotein (encoded byABCB1) has been implicated as the major cause of its emergence. Wnt signaling has been demonstrated to be important in several aspects of CML. Recently, Wnt signaling was linked toABCB1regulation through its canonical pathway, which is mediated by β-catenin, in other types of cancer. In this study, we investigated the involvement of the Wnt/β-catenin pathway in the regulation ofABCB1transcription in CML, as the basal promoter ofABCB1has several β-catenin binding sites. β-catenin is the mediator of canonical Wnt signaling, which is important for CML progression.Methods: In this work we used the K562 cell line and its derived MDR-resistant cell line Lucena (K562/VCR) as CML study models. Real time PCR (RT-qPCR), electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), flow cytometry (FACS), western blot, immunofluorescence, RNA knockdown (siRNA) and Luciferase reporter approaches were used.Results: β-catenin was present in the protein complex on the basal promoter ofABCB1in both cell linesin vitro, but its binding was more pronounced in the resistant cell linein vivo. Lucena cells also exhibited higher β-catenin levels compared to its parental cell line.Wnt1andβ-catenindepletion and overexpression of nuclear β-catenin, together with TCF binding sites activation demonstrated thatABCB1is positively regulated by the canonical pathway of Wnt signaling.Conclusions: These results suggest, for the first time, that the Wnt/β-catenin pathway regulatesABCB1in CML.

24 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAndré L. Mencalha
André L. Mencalha
RBRenata Binato
Renata Binato
GFGerson Moura Ferreira
Gerson Moura Ferreira
BRBarbara Du Rocher
Barbara Du Rocher
EAEliana Abdelhay
Eliana Abdelhay
The forkhead box (Fox) M1 gene belongs to a superfamily of evolutionarily conserved transcriptional regulators that are involved in a wide range of biological processes, and its deregulation has been implicated in cancer survival, proliferation and chemotherapy resistance. However, the role of FoxM1, the signaling involved in its activation and its role in leukemia are poorly known. Here, we demonstrate by gene promoter analysis, Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays that FoxM1 is a new target of the STAT3 transcriptional activator. Additionally, FoxM1 is transcriptionally dependent on STAT3 signaling activation. Furthermore, we verified that FoxM1 is crucial for K562 cell proliferation, cell cycle checkpoints and viability and could be related to chemotherapeutic resistance. By microarray analysis, we determined the signaling pathways related to FoxM1 expression and its role in DNA repair using K562 cells. Our results revealed new signaling involved in FoxM1 expression and its role in leukemic cells that elucidate cellular mechanisms associated with the development of leukemia and disease progression.

7 October 2010 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
JJJulio Cesar Madureira de Freitas Junior
Julio Cesar Madureira de Freitas Junior
BSBárbara Du Rocher D’aGuiar Silva
Bárbara Du Rocher D’aGuiar Silva
WSWaldemir Fernandes de Souza
Waldemir Fernandes de Souza
WAWallace Martins de Araújo
Wallace Martins de Araújo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
JMJose Morgado-Diaz
Jose Morgado-Diaz

6 May 2014 in Epigenetics
Verified
Journal Article
Closed access
SCStephany Corrêa
Stephany Corrêa
RBRenata Binato
Renata Binato
BRBárbara Du Rocher
Bárbara Du Rocher
GFGerson Moura Ferreira
Gerson Moura Ferreira
PCPaola Cappelletti
Paola Cappelletti
EAEliana Abdelhay
Eliana Abdelhay
One of the potential mechanisms of imatinib mesylate (IM) resistance in chronic myeloid leukemia (CML) is increased level of P-glycoprotein (Pgp). Pgp is an efflux pump capable of activating the mu...

2 May 2012 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JDJulio Cesar Madureira De‐Freitas‐Junior
Julio Cesar Madureira De‐Freitas‐Junior
LBLilian Golçalves Bastos
Lilian Golçalves Bastos
CFCarlos Alberto Freire‐Neto
Carlos Alberto Freire‐Neto
BRBárbara Du Rocher
Bárbara Du Rocher
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
JMJose Morgado-Diaz
Jose Morgado-Diaz